Short hairpin RNAs against eotaxin or interleukin-5 decrease airway eosinophilia and hyper-responsiveness in a murine model of asthma

Journal of Gene Medicine

Volumn 11, Issue 2, 2009, Pages 112-118

  Huang, Hsin Ying ^a   Lee, Chen Chen ^a,b   Chiang, Bor Luen ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Airway hyper responsiveness; Eotaxin; IL 5; ShRNA

Indexed keywords

EOTAXIN; INTERLEUKIN 5; LENTIVIRUS VECTOR; OVALBUMIN; SHORT HAIRPIN RNA; BETA CHEMOKINE; UNTRANSLATED RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; EOSINOPHIL; EOSINOPHILIA; FEMALE; GENE TARGETING; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BRONCHUS HYPERREACTIVITY; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; LOEFFLER PNEUMONIA; METABOLISM; RNA INTERFERENCE;

LENTIVIRUS; MURINAE;

ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CHEMOKINES, CC; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; PULMONARY EOSINOPHILIA; RNA INTERFERENCE; RNA, UNTRANSLATED;

EID: 62249100734     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1285     Document Type: Article

References (37)

1. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004; 25: 477-482.
2. Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982; 2: 11-16.
3. Fujisawa T, Kato Y, Nagase H, et al. Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol 2000; 106: 507-513.
4. Sanderson CJ. Interleukin-5: an eosinophil growth and activation factor. Dev Biol Stand 1988; 69: 23-29.
5. Yamaguchi Y, Suda T, Suda J, et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988; 167: 43-56.
6. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101-3109.
7. Wiktor-Jedrzejczak W. Eosinophil development. Immunol Today 1993; 14: 238.
8. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995; 182: 1169-1174.
9. Farahi N, Cowburn AS, Upton PD, et al. Eotaxin-1/CC chemokine ligand 11: a novel eosinophil survival factor secreted by human pulmonary artery endothelial cells. J Immunol 2007; 179: 1264-1273.
10. Walker C, Virchow JC Jr, Bruijnzeel PL, Blaser K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991; 146: 1829-1835.
11. Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994; 179: 703-708.
12. Till S, Li B, Durham S, et al. Secretion of the eosinophilactive cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopic asthmatics, and atopic and non-atopic controls. Eur J Immunol 1995; 25: 2727-2731.
13. Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997; 156: 704-708.
14. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 92: 313-324.
15. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183: 195-201.
16. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996; 4: 15-24.
17. Popescu FD. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005; 9: 840-853.
18. Huang HY, Lee CC, Chiang BL. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness. Gene Ther 2008; 15: 660-667.
19. Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 1999; 6: 715-728.
20. Cui Y, Iwakuma T, Chang LJ. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 1999; 73: 6171-6176.
21. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999; 261: 120-132.
22. Glaab T, Mitzner W, Braun A, et al. Repetitive measurements of pulmonary mechanics to inhaled cholinergic challenge in spontaneously breathing mice. J Appl Physiol 2004; 97: 1104-1111.
23. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989; 19: 701-705.
24. Dorman SC, Sehmi R, Gauvreau GM, et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 2004; 169: 565-572.
25. Park CS, Choi YS, Ki SY, et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur Respir J 1998; 12: 872-878.
26. Main S, Handy R, Wilton J, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther 2006; 319: 1395-1404.
27. Pereira S, Clark T, Darby Y, et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis. J Allergy Clin Immunol 2003; 111: S268.
28. Salib R, Salagean M, Lau L, et al. The anti-inflammatory response of anti-eotaxin monoclonal antibody CAT-213 on nasal allergen-induced cell infiltration and activation. J Allergy Clin Immunol 2003; 111: S347.
29. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113: 115-119.
30. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006; 118: 1133-1141.
31. Leckie MJ, 10 Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-2148.
32. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003; 21: 799-803.
33. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655-1659.
34. Lee CC, Huang HY, Chiang BL. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and yyperresponsiveness. Mol Ther 2008; 16: 60-65.
35. Pebernard S, Iggo RD. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 2004; 72: 103-111.
36. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
37. Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003; 278: 44312-44319.